These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 31894386)

  • 1. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
    Tian P; Liu Y; Zeng H; Tang Y; Lizaso A; Ye J; Shao L; Li Y
    J Cancer Res Clin Oncol; 2020 Apr; 146(4):935-944. PubMed ID: 31894386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
    Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
    Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
    Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
    Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
    Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
    Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
    Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
    J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
    Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
    Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
    Bilgin B; Şendur MAN; Yücel Ş; Hizal M; Güner G; Akyürek N; Erol C; Akıncı MB; Dede DŞ; Yalçın B; Kılıçkap S
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2637-2643. PubMed ID: 33528638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
    Zhang Y; Zeng L; Zhou C; Li Y; Wu L; Xia C; Jiang W; Hu Y; Liao D; Xiao L; Liu L; Yang H; Xiong Y; Guan R; Lizaso A; Mansfield AS; Yang N
    J Thorac Oncol; 2020 Jun; 15(6):1027-1036. PubMed ID: 32112982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics of patients with surgically resected lung cancer having tumours harboring anaplastic lymphoma kinase fusion protein.
    Chen B; Jiang Z; Li C; Lu H
    J Pak Med Assoc; 2020 Apr; 70(4):747-750. PubMed ID: 32296229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
    Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
    Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.